Martin Shkreli is a former pharmaceutical entrepreneur and financier who became widely known for raising the price of a life-saving drug and for his high-profile legal and market conduct. This profile explains his major business moves, the controversies that defined his public career, and the ongoing consequences for pharmaceutical pricing and regulation. Readers gain a clear, evidence-based understanding of who he is, what he did, and why the story remains relevant to drug development, pricing transparency, and investor protections.
Early Life and Education
Martin Shkreli grew up in New York City and demonstrated an early aptitude for science and mathematics. He attended Hunter College High School and later studied biology at Baruch College, where he first developed an interest in the pharmaceutical industry. His academic training and internships in finance laid the groundwork for his later career in securities trading and pharmaceutical development.
Career in Finance and Pharmaceuticals
Shkreli began his career as a hedge fund analyst, where he focused on identifying overvalued biotech and pharmaceutical companies. He later founded several investment firms, including one that specialized in short selling. In the early 2010s, he shifted toward pharmaceutical development, acquiring rights to existing drugs and establishing companies that could commercialize or license these assets.
Turing Pharmaceuticals and Daraprim
In 2015, Turing Pharmaceuticals acquired the rights to Daraprim, a decades-old antiparasitic drug used to treat toxoplasmosis. Shortly after the acquisition, Turing dramatically increased the wholesale price of the drug, drawing national attention. The move sparked widespread criticism from policymakers, patient advocates, and media, and became emblematic of concerns about drug pricing in the United States.
Other Business Ventures and Securities Activity
Beyond Turing, Shkreli founded or advised multiple life sciences companies and launched a specialty pharmacy. In parallel, he remained active in public markets, promoting biotech and pharmaceutical equities. His investment strategies and public statements often generated significant volatility, leading to heightened scrutiny from regulators and exchanges.
Regulatory and Legal Challenges
Shkreli’s practices drew investigations from the Securities and Exchange Commission and other authorities. Allegations included misleading investors, improper use of company funds, and securities fraud. In parallel, lawmakers examined the pricing of medications like Daraprim, questioning the ethics and transparency of such increases. These inquiries culminated in a high-profile criminal conviction and a lengthy ban from the securities industry.
Key Events Timeline
| Date or Period | Event | Why It Matters |
|---|---|---|
| 2011–2014 | Rise as a biotech short seller and founder of investment vehicles | Established reputation for aggressive trading and contrarian positions |
| 2015 | Turing Pharmaceuticals acquires Daraprim and raises price substantially | Catalyzed national debate on drug pricing and affordability |
| 2015–2016 | SEC and Department of Justice investigations intensify | Increased regulatory and public scrutiny of pharmaceutical pricing and investor practices |
| 2017 | Criminal conviction and subsequent sentencing | Resulted in multiyear prison sentence and permanent industry ban |
| 2017 onward | Restricted activity and ongoing legal obligations | Marked transition out of active market roles and into supervised release |
Public and Industry Reaction
The pricing of Daraprim and related actions provoked strong reactions from patient advocacy groups, clinicians, and policymakers. Many argued that the move exemplified systemic problems in drug pricing and patent management. In parallel, other pharmaceutical and biotech executives distanced themselves from his tactics, and regulators increased focus on transparency around pricing decisions and conflicts of interest.
Lasting Impact on Pharma and Regulation
Although Shkreli is no longer active in the industry, his case influenced ongoing discussions about drug affordability, investor ethics, and regulatory enforcement. Policymakers have referenced his conduct when debating transparency rules, reimbursement practices, and anti-fraud measures. The episode also shaped public perceptions of pharmaceutical entrepreneurship and the responsibilities that come with controlling essential medicines.
Current Status and Relevance
Shkreli remains subject to legal restrictions, including bans from the securities industry and ongoing obligations tied to prior settlements and judgments. His story continues to inform conversations about accountability in life sciences, the limits of price setting, and the long-term implications of controversial business models. As regulatory frameworks evolve, the case is often cited in policy discussions and educational contexts related to corporate responsibility in pharmaceuticals.